BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The late-stage gene therapy pipeline is rapidly evolving\, wit
 h 10+ approvals across the FDA and EMA in the past year and several more 
 BLA filings and decisions expected by the beginning of 2024.\n\nAs moment
 um builds towards significantly higher numbers of active later-stage clin
 ical trials\, the importance drug developers and regulators are placing o
 n comparability is increasing too. That's why the 4th Gene Therapy Compar
 ability Summit will be back in February 2024\, hot on the heels of 2023 a
 pprovals\, to share the lessons learnt by biopharma directly dealing with
  comparability for their clinical-stage assets.\n\nJoin us in February to
  design and implement an effective comparability study\, significantly de
 -risk costly delays to clinical programs and ultimately increase the chan
 ces of approval.\n\n&nbsp\;\n\nDate and Time: On Tuesday February 13\, 20
 24 at 9:00 am to Thursday February 15\, 2024 at 3:00 pm\n
DTEND:20240215T150000
DTSTAMP:20260307T150303Z
DTSTART:20240213T090000
LOCATION:Hilton Boston Back Bay\, 40 Dalton Street\, Boston\, Massachusett
 s\, 02115\,
SEQUENCE:0
SUMMARY:The late-stage gene therapy pipeline is rapidly evolving\, with 10
 + approvals across the FDA and EMA in the past year and several more BLA 
 filings a...
UID:95907cc9-92ee-445a-8460-2e508feddc16
END:VEVENT
END:VCALENDAR